Cervical cancer is the most common gynecological malignancy. The high incidence age of in situ cancer is 30 to 35 years old, and that of invasive cancer is 45 to 55 years old; in recent years, there is a trend of its incidence becoming younger. The common application of cervical cytology screening in recent decades has enabled early detection and treatment of cervical cancer and precancerous lesions, and the incidence and mortality rate of cervical cancer have been significantly reduced. Atypical hyperplasia, such as mild atypical hyperplasia on biopsy, should be treated as inflammation for the time being and followed up by scraping and biopsy in half a year if necessary. Those with persistent lesions can continue to be observed. For those diagnosed with moderate atypical hyperplasia, laser, freezing and electro-ironing should be applied. For severe atypical hyperplasia, total hysterectomy is generally advocated. If there is an urgent need for fertility, close follow-up can be performed regularly after conical resection. 2.Carcinoma in situ Generally, total hysterectomy is advocated, preserving both ovaries; some advocate the simultaneous removal of 1~2cm of vagina. In recent years, laser treatment has been used at home and abroad, but close follow-up is necessary after treatment. 3.Microscopic early infiltrating carcinoma Generally, most of them advocate enlarged total hysterectomy and vaginal tissue of 1~2 cm. Because the possibility of lymphatic metastasis of microscopic early infiltrating cancer is very small, it is not necessary to eliminate pelvic lymphatic tissue. 4.Infiltrating carcinoma Treatment methods should be based on clinical stage, age and general condition, and equipment conditions. Commonly used treatment methods include radiation, surgery and chemotherapy. Generally speaking, radiotherapy can be applied to patients of all stages; the efficacy of surgery is similar to radiotherapy for stages Ib to IIa; cervical adenocarcinoma is slightly less sensitive to radiotherapy and should be treated by a combination of surgical resection plus radiotherapy. Surgical treatment: Extensive hysterectomy and pelvic lymph node elimination. The scope of resection includes the whole uterus, bilateral adnexa, upper vagina and paravaginal tissues as well as the lymph nodes in the pelvic cavity (paracervical, foramen ovale, internal iliac, external iliac and inferior common iliac lymph nodes). The operation should be thorough, safe, strictly control the indications and prevent complications. Surgical complications and management 1.Surgical complications include intraoperative bleeding, postoperative pelvic infection, lymphatic cyst, retention, urinary tract infection and ureterovaginal fistula. In recent years, due to the improvement of surgical methods and anesthesia techniques, the application of prophylactic antibiotics, and the use of postoperative extraperitoneal negative pressure drainage, the incidence of the above complications has been significantly reduced. Radiation therapy is the first choice for cervical cancer and can be applied to all stages of cervical cancer. The scope of radiation includes the cervix, the affected vagina, uterine body, parametrium and pelvic lymph nodes. Internal radiation mainly targets the primary cervical site and its adjacent areas, including the body of the uterus, the upper part of the vagina and the adjacent parametrial (“A”) tissues. External irradiation is directed at the area of the pelvic lymph nodes (“B”). The internal radiation source is intracavitary radium (Ra) or 137 cesium (137Cs), targeting mainly the primary cervical lesions. The external radiation source is 60 drill (60Co), which mainly targets metastases outside the primary lesion, including the pelvic lymph node drainage area. At present, internal radiation is mostly advocated for early-stage cervical cancer. For advanced stage cancer, especially those with huge local tumor, active bleeding or infection, external irradiation is preferred. V. Chemotherapy So far, cervical cancer is not sensitive to most anti-cancer drugs, and the efficiency of chemotherapy does not exceed 15%.